BioAtla Secures $40M SPV Deal to Propel Ozuriftamab Vedotin into OPSCC Trials
BioAtla partners with GATC Health to advance Ozuriftamab Vedotin into a registration trial for second‑line OPSCC, marking a pivotal step toward new antibody‑based cancer therapy.
2 minutes to read